Advisory Board August 29, 2024
Major pharmaceutical companies are making moves to increase patient access to their medications, with Eli Lilly offering vials of its popular weight-loss drugs at cheaper prices and Pfizer launching its own direct-to-consumer (DTC) platform.
How to navigate the evolving high-cost drug landscape
Eli Lilly sells vials of its weight-loss drugs directly to consumers
Eli Lilly announced new plans to begin selling low-dose vials of its weight-loss drug, Zepbound, directly to consumers. Compared to pre-filled doses, the vials will be sold at a significantly cheaper cost.
A one-month supply of the 2.5-milligram dose of Zepbound will cost $399, while a one-month supply of the five-milligram dose will cost $549. In comparison, pre-filled doses of Zepbound cost $1,059 a month, regardless of...
Today's Sponsors
Today's Sponsor